[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gut--microbiota\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gut--microbiota":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,64,102,127,152,196,227,257,290,321],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627026","alterations-of-gut-derived-uremic-toxins-and-microbiome-metabolites-by-multispecies-synbiotic-100627026",false,"NCT07443280","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic Supplementation in Hemodialysis Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months\n\nExclusion Criteria:\n\n1. Use of probiotic supplements within the last month;\n2. Hospitalization within the past month for acute infections or CKD-related complications;\n3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);\n4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;\n5. Use of antibiotics or immunosuppressive therapy within the preceding three months.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis frequently exhibit significant gut microbiota dysbiosis and increased intestinal permeability. These alterations enable the translocation of endotoxins and gut-derived uremic toxins-such as indoxyl sulfate and p-cresyl sulfate-into the systemic circulation, exacerbating systemic inflammation, elevating cardiovascular risk, and accelerating disease progression.\n\nMultispecies synbiotic supplementation has emerged as a promising intervention to restore gut microbial equilibrium, strengthen intestinal barrier function, and reduce the systemic load of harmful microbial metabolites. Through modulation of inflammatory pathways and reduction of circulating uremic toxins, synbiotic hold potential to improve clinical outcomes in this vulnerable population.\n\nAlthough preclinical and some clinical evidence suggests benefits of probiotic therapy, comprehensive clinical trials specifically examining multispecies synbiotic effects on gut inflammatory markers, gut derived metabolite profiles, and uremic toxin levels in hemodialysis patients remain limited. This pilot study aims to address this gap by investigating the biological and clinical effects of a 12-week multispecies regimen in adult maintenance hemodialysis patients.",[26,27,28],"Symbiotic","Uremic Toxins","Gut -Microbiota",[30,31,32,33],"multispecies synbiotic","uremic toxins","gut microbiome","hemodialysis patients","RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":38},"2026-05-04",{"date":42,"type":20},"2026-12-31",{"name":44,"class":45},"Tungs' Taichung Metroharbour Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":63,"locationsCount":46},"100628407","modulation-of-gut-microbiota-composition-and-gut-permeability-profiles-by-multispecies-synbiotic-supplementation-in-hemodialysis-patients-100628407","NCT07461233","Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients",{"count":19,"type":20},[23],"Chronic kidney disease (CKD) patients undergoing maintenance hemodialysis experience profound alterations in their gut microbiota, leading to dysbiosis and increased gut permeability. This disruption facilitates the translocation of endotoxins and gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate into the systemic circulation, contributing to heightened systemic inflammation, cardiovascular disease risk, and accelerated CKD progression.\n\nSynbiotic supplementation, particularly multispecies formulations, has emerged as a promising therapeutic strategy to restore gut microbial balance, enhance intestinal barrier integrity, and reduce the systemic burden of deleterious microbial metabolites. These probiotics potentially improve clinical outcomes by modulating inflammatory pathways and decreasing circulating levels of uremic toxins.\n\nDespite these insights, few clinical trials have comprehensively assessed the effects of multispecies synbiotic on fecal microbiome composition, gut permeability and uremic toxin profiles in hemodialysis patients. This pilot study aims to fill this gap by evaluating the modulatory effects of a 12-week multispecies synbiotic intervention.",[26,27,28,56,57],"Gut Permeability","Hemodialysis",[30,33,31,32,59],"gut permeability",{"date":37,"type":38},{"date":40,"type":38},{"date":42,"type":20},{"name":44,"class":45},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100638243","impact-of-a-novel-functional-snack-on-perimenopausal-symptoms-and-well-being-100638243","NCT07599930","Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being","Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial","SWAP","Inclusion Criteria:\n\n* Adults aged 40 to 55\n* Score 14 or higher on the Menopause Rating Scale\n* For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.\n\nExclusion Criteria:\n\n* People who consume more than 15g of fibre a day\n* People who consume more than 2 cups of coffee or tea a day\n* People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day\n* People who do not have any intolerances or allergies to the following:\n* Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts\n* Chia seeds\n* Pumpkin seeds\n* Sunflower seeds\n* Dates\n* Gluten\n* Dairy\n* Oats\n* Barley\n* Soya\n* People who smoke or vape or have smoked or vaped in the last 2 years\n* People who consume more than 21 drinks a week or have a history of excess alcohol intake\n* People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, malignancies, cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems\n* People receiving drug treatment for lipid metabolisms (e.g., statins)\n* People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids) or aspirin\n* People taking antihypertensive drugs\n* People who take antibiotics or bacterial agents (Probiotics) within 1 month\n* People who take vitamin\u002Fdietary supplements within 1 month\n* Pregnant women, women ready for pregnancy, and nursing mothers\n* cardiac arrhythmia\n* renal failure\n* heart failure (NYHA II-IV)\n* diabetes mellitus\n* Malignant disease\n* People who have participated in a biomedical study within the past 3 months\n* Women who require hormone replacement therapy during the development of the protocol.",true,"FEMALE","40 Years","55 Years",{"count":77,"type":20},20,[23],"This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.\n\nHypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.\n\nMain research questions:\n\nDoes eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?",[81,82,83,84,85,28],"Perimenopause","Perimenopause-Related Depression","Mood","Sleep","Quality of Life",[87,88,89,90,91,92],"phytochemical","fibre","mood","sleep","quality of life","gut","2026-05-14",{"date":95,"type":38},"2026-05-20",{"date":97,"type":38},"2026-04-24",{"date":99,"type":20},"2026-12",{"name":101,"class":45},"King's College London",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":72,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100626711","impact-of-a-cricket-and-black-soldier-fly-larvae-fortified-cracker-on-the-gut-microbiome-and-iron-status-in-malagasy-schoolchildren-100626711","NCT07439185","Impact of a Cricket and Black Soldier Fly Larvae-Fortified Cracker on the Gut Microbiome and Iron Status in Malagasy Schoolchildren","Inclusion criteria for children\n\n* Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools\n* Caregiver or legal guardian is willing to provide informed consent\n* Child is willing to provide informed assent\n\nExclusion criteria for children\n\n* Child age is outside the preferred age range (9 to 13 years)\n* Not enrolled in the participating schools\n* Unable or unwilling to comply with the study requirements\n* Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g\u002FdL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.\n* Covid-exposure or symptoms: loss of smell or taste\n* History of food allergies or adverse reactions to any edible insects\n* Chronic severe medical condition or congenital anomalies requiring frequent medical attention or interfering with dietary consumption\n* Caregiver does not give consent, or child does not assent\n\nInclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)\n\nExclusion criteria for parents\n\n• Caregiver does not consent to participate","9 Years","13 Years",{"count":111,"type":20},650,[23],"The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.\n\nSpecifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).",[28,115,116],"Inflamation","Iron Absorption","NOT_YET_RECRUITING","2026-02-23",{"date":120,"type":38},"2026-02-27",{"date":122,"type":20},"2026-02",{"date":124,"type":20},"2026-06",{"name":126,"class":45},"Cornell University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":46},"100579735","dietary-wild-blueberries-and-joint-health-100579735","NCT06828159","Dietary Wild Blueberries and Joint Health","Effects of Dietary Wild Blueberries on Gut Health and Inflammation and Joint Pain","Inclusion Criteria:\n\n* Adults with documented multi-joint\u002Fknee arthritis\n\nExclusion Criteria:\n\n* inability to give informed consent\n* pregnancy or lactation\n* planned knee replacement surgery\n* allergy or contraindication to berries\n* recent trauma of the knee responsible of the symptomatic knee\n* intra-articular injection in the target knee\u002Fhip in the last 3 months\n* oral corticosteroid therapy ≥ 5 mg\u002Fday (prednisone equivalent) at baseline\n* use of berry extracts in the last 3 months\n* special diets\n* cancer treatment\n* bone diseases","75 Years",{"count":136,"type":20},50,[23],"The goal of this proposed study is to examine the effects of dietary wild blueberries on gut microbiome, serum markers of inflammation, and joint function in adults. Each participant will consume 25g freeze-dried blueberries or matched placebo powder for 12 weeks, with a 2-week washout phase between.",[28,140,141,142],"Inflammation Biomarkers","Pain Assessment","Joint Pain","2025-11-03",{"date":145,"type":38},"2025-11-05",{"date":147,"type":38},"2025-09-01",{"date":149,"type":20},"2028-03",{"name":151,"class":45},"University of Nevada, Las Vegas",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":72,"sex":16,"minAge":4,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":179,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100609268","infant-microbiota-restoration-with-maternal-microbes-100609268","NCT07212361","Infant Microbiota Restoration With Maternal Microbes","MaMi","Inclusion Criteria:\n\n* Healthy mother and healthy pregnancy\n* Singleton pregnancy,\n* Mothers who speak Finnish or Swedish\n* Mothers who are planning to breastfeed or give breastmilk by bottle to the infant\n* Infants who are expected to be healthy and who will not require BCG vaccination.\n\nExclusion Criteria:\n\n* Participants who lives further than a 2-hour drive from Meilahti, Helsinki, Finland\n* Mothers who are not planning to breastfeed or feed breastmilk by bottle to the infant\n* Mothers who are diagnosed with gestational diabetes, pre-eclampsia or who have been receiving antibiotics during the pregnancy or delivery\n* Premature infants born before the pregnancy week 37\n* Infants, who are born by urgent cesarean section or emergency cesarean section\n* Infants, who receive antibiotics during the first week of life\n* Infants, who are diagnosed with a disease, congenital anomaly or who receive less than 9 Apgar points at 5 minutes.\n* Infants, who receive BCG-vaccine","50 Years",{"count":161,"type":20},100,[23],"The goal of this clinical trial is to test the ability of different bacterial products in restoring natural gut microbiota in C-section born infants. The main question it aims to answer is:\n\nDo maternally derived strains of bacteria perform better than commercially available probiotic strains in restoring the gut microbiota of C-section born infants? Researchers will compare the gut microbiota of treated infants to that of untreated C-section born infants and untreated vaginally born infants to see if the bacterial treatments cause the microbiota to resemble that of vaginally born infants.\n\nParticipants will be given a bacterial product orally once daily for either one or four weeks and be asked to collect faecal, urine and saliva samples.",[165,28,166,167,168,169,170,171,172,173,174,175,176,177,178],"Infant, Newborn","Gut Dysbiosis","Cesarean Delivery Affecting Newborn","Cesarean Section","Vaginal Delivery","Gastrointestinal Microbiota","Microbiota, Cesarean Section, Probiotics, Dysbiosis","Feces","Delivery, Obstetric","Microbiota","Microbiology","Humans","Pregnancy","Neonate",[180,181,182,183,184,185],"Infant","newborn","cesarean section","neonate","restore","gut microbiota","2025-09-30",{"date":188,"type":38},"2025-10-08",{"date":190,"type":38},"2025-07-17",{"date":192,"type":20},"2035-12-31",{"name":194,"class":45},"University of Helsinki",2,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":46},"100599223","walnuts-as-an-infant-solid-food-for-health-100599223","NCT07081698","Walnuts as an Infant Solid Food for Health","Walnut as a First Food During Complementary Feeding on Gut Microbiota and Immunity Development in Breastfed Infants","WISH","Inclusion Criteria:\n\n* Full term: gestational age ≥ 37 weeks\n* Generally healthy without conditions that would affect normal growth\n* No significant consumption of complementary food (e.g., no more than 1 oz of solid foods per week)\n* Exclusively breastfed (\\\u003C 2 weeks of cumulative formula exposure)\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Pregnant women\n* Prisoners","5 Months",{"count":206,"type":20},90,[23],"The objective is to investigate the effect of walnuts on gut microbiota, inflammatory markers, atopic dermatitis status, and indices of allergy outcomes in breastfed infants during early complementary feeding.\n\nThe three primary aims include:\n\nAim 1: Evaluate the effect of walnut consumption on gut microbiota structure and function, inflammation, atopic dermatitis, and allergy outcomes.\n\nAim 2: Evaluate the impact of walnut consumption on infant growth trajectories and risk of overweight.\n\nAim 3 (exploratory): Identify walnut-specific food signatures that are associated with gut microbiota and immunity biomarkers using a novel nutri-metabolomics technique.",[28,210,211],"Inflammatory Markers","Infant Development",[213,214,180,215,216,217],"Walnut","Microbiome","Pediatric","Nutrition","Health","2025-07-16",{"date":220,"type":38},"2025-07-23",{"date":222,"type":38},"2025-05-18",{"date":224,"type":20},"2027-12-31",{"name":226,"class":45},"Colorado State University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":72,"sex":16,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":246,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100595529","probiotics-and-active-aging-enhancing-gut-health-100595529","NCT07033637","Probiotics and Active Aging: Enhancing Gut Health","Promoting Health Through Symbiosis: Exploring the Relationship Between Gut Microbiota, Probiotics, and Physical Activity in Older Adults","PAAEGH","Inclusion Criteria:\n\n* Adults aged 60 years or older.\n* Residents of Castilla-La Mancha or Madrid.\n* Able to provide informed consent.\n* For the intervention group: enrolled in a municipal physical activity program with a minimum frequency of 2 sessions per week.\n* Willing to participate in all assessments and follow study instructions.\n* Consent: Participants must provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Recent serious musculoskeletal injuries (e.g., muscle tears, ligament ruptures, fractures).\n* Current symptoms during exercise such as chest pain, dizziness, or joint pain.\n* Uncontrolled hypertension (≥160\u002F100 mmHg).\n* Recent cardiac failure or infectious disease (e.g., meningitis, hepatitis, flu).\n* Chronic gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, IBS).\n* Regular use of medications affecting gut motility or microbiota (e.g., laxatives \\>3 times\u002Fweek).\n* Immunodeficiency (e.g., HIV, active cancer).\n* Use of antibiotics (oral or parenteral) within 4 weeks prior to the study.\n* Regular intake of probiotic supplements or foods (e.g., Actimel) within 2 weeks prior to the study.","60 Years",{"count":206,"type":20},[23],"The general objective of this clinical trial is to assess the physical fitness and gut microbiota of older adults, thereby highlighting the importance of focusing on health maintenance. By making use of available resources and fostering collaboration among the elements involved in the study, more specific objectives can be defined:\n\n1. To determine the state of the gut flora in older adults through the analysis of the intestinal microbiota.\n2. To identify changes in the intestinal microbiota resulting from the intake of probiotics in older adults.\n3. To evaluate the effects of the intestinal microbiota in older adults participating in a training programme.\n4. To assess the physical fitness and perceived quality of life in older adults who engage in sport activities supported by technology.\n\nParticipants will:\n\n* Perform physical tests such as the 6-Minute Walk Test (6MWT), the Timed Up and Go (TUG), and the Sit-to-Stand test.\n* Complete wellbeing questionnaires to assess their perceived quality of life and health status.\n* Complete dietary habit questionnaires.\n* Provide stool samples for microbiota analysis.\n* Take part in exercise interventions or placebo exercise sessions, depending on their assigned group.",[28,240,241,242,243,244,245],"Older People","Physical Activity","Physical Fitness","Mental Health","Probiotic","Healthy",[247,185,248],"older people","physical activity","2025-06-13",{"date":251,"type":38},"2025-06-24",{"date":147,"type":20},{"date":254,"type":20},"2026-06-30",{"name":256,"class":45},"Jose Luis Felipe",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":72,"sex":16,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":269,"conditions":270,"keywords":275,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":46},"100575657","associations-between-dietary-intake-and-cardiometabolic-and-gut-microbiota-outcomes-100575657","NCT06775132","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes in Singapore Adults","Inclusion Criteria:\n\n1. Able to give informed consent\n2. Adults 21-80 years old\n3. English-literate\n4. Have venous access sufficient to allow for blood sampling as per the protocol\n5. No drastic change of diet for the past 1 year\n6. If taking medication, has been consistently taking antihypertensive\u002Fcholesterol-lowering\u002Ftype-2 diabetic medication for more than 5 years prior to starting the study.\n\nExclusion Criteria:\n\n1. Taking dietary supplements and fermented foods, which may impact the gut microbiota (e.g. antibiotics, prebiotics, probiotics, yogurt, kimchi) 2 months before starting the 1st study visit only.\n2. Taking dietary supplements or medications, which may impact sleep outcomes (e.g. Nutritional Shakes (e.g. Ensure), tryptophan, 5-hydroxytryptophan or melatonin supplementations) 1 month before starting the study.\n3. Taking dietary supplements which may impact the eye outcomes (e.g. Vitamin A, vitamin A-containing multivitamin) 2 months before starting the study.","21 Years","80 Years",{"count":267,"type":20},240,"OBSERVATIONAL","This cross-sectional study aims to investigate the associations between dietary intake, cardiometabolic health markers, and gut microbiota composition in Singapore adults.",[271,28,272,273,274],"Cardiometabolic Risk Factors","Skin Condition","Cognitive Ability, General","Sleep Quality",[276,277,278,279,280],"Endothelial progenitor cells","Gut microbiota","Cardiovascular diseases risk factors","MoCA","Advanced glycation end products","2025-05-19",{"date":283,"type":38},"2025-05-21",{"date":285,"type":38},"2025-02-03",{"date":287,"type":20},"2025-12-30",{"name":289,"class":45},"National University of Singapore",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":297,"maxAge":17,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":302,"conditions":303,"keywords":309,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":4},"100577070","phase-1-efficacy-and-safety-of-oral-probiotics-on-ocular-symptoms-and-gut-microbiome-of-children-with-vernal-keratoconjunctivitis-100577070","NCT06793514","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis: a Double-blind Clinical Trial Study","Inclusion Criteria:1- Patients whose diagnosis of vernal keratoconjunctivitis is confirmed based on clinical criteria. 2-Patients with an age range of 4 to 18 years. 3-Patients who have not received drug treatment for vernal keratoconjunctivitis disease recently.\n\n\\-\n\nExclusion Criteria:1-Having other eye diseases (except refractive error) 2-Change in the diagnosis of the disease during the study 3-Antibiotics, anti-inflammatory drugs, immunosuppressive drugs 4-History of known gastrointestinal diseases (such as IBD, Celiac,...) 5- History of digestive problems in the last two weeks 6- Lack of consent to participate in the study 7- Having an eye infection in the last one month 8- People who were athletes or involved in intense physical activity 9- Smoking, alcohol and drugs. 10- Using drugs that affect appetite, bowel movements, and nutrient absorption 11- Using prebiotics, probiotics or synbiotics in the last 3 months 12- People who have been on a diet to lose or gain weight in the last 3 months 13- People who have undergone gastrointestinal surgery. 14- Changing the patient's diagnosis in the course of treatment 15- Failure to follow up the patient at the specified times for the visit and assessment of the patient's bed 16- Taking fat-reducing drugs 17-Oral hypoglycemic drugs, insulin, antihypertensive drugs-18- Diuretics, laxatives, antacids 19-Food supplements in the last 3 months.\n\n\\-","4 Years",{"count":299,"type":20},32,[301],"PHASE1","The primary goal of this study is to determine the effects of oral probiotics on the severity of ocular symptoms and the alterations of the gut microbiome of children (4-18 years old) with vernal keratoconjunctivitis. The current study will also assess the safety of oral probiotics among children with vernal keratoconjunctivitis. The main questions it aims to answer: 1- Does treatment with oral probiotics improve the severity of ocular symptoms in children with vernal keratoconjunctivitis? 2- Does treatment with oral probiotics alter the gut microbiome of children with vernal keratoconjunctivitis? Researchers will compare the ocular symptoms and gut microbiome between two groups receiving oral probiotics and placebo among children with vernal keratoconjunctivitis.\n\nParticipants The participants will receive the oral probiotics and placebo ever day for one month.\n\nRecord their regimen and keep a diary of their symptoms.",[244,304,305,306,307,308],"Ocular Surface Disease","Ocular Diseases","Ocular Dryness","Gut Microbiome Dysbiosis","Gut -microbiota",[244,310,311,32],"Vernal keratoconjunctivitis","Clinical trial","2025-01-21",{"date":314,"type":38},"2025-01-27",{"date":316,"type":20},"2025-02-01",{"date":318,"type":20},"2025-06-01",{"name":320,"class":45},"Mohsen Pourazizi",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":333,"conditions":334,"keywords":338,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100576953","phase-4-impact-of-probiotics-on-gut-microbiome-during-antibiotic-prophylaxis-in-elective-orthopedic-surgery-100576953","NCT06791993","Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery","Impact of Probiotics Combined with Antibiotic Prophylaxis on Gut Microbiome Balance in Patients Undergoing Elective Orthopedic Surgery, Double-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Scheduled for elective low-risk orthopedic surgery (carpal tunnel release, A1 pulley release, knee arthroscopic surgery).\n\nExclusion Criteria:\n\n* History of infection or antibiotic use within the last 12 weeks.\n* Use of routine probiotics, vitamins, or herbal supplements in the last 4 weeks.\n* Known allergy to beta-lactam or cephalosporin antibiotics.\n* History of autoimmune disease, uncontrolled systemic disease, or chronic inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).\n* History of chronic intestinal diseases such as small intestine bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or celiac disease.\n* Increased risk of infection due to medical comorbidities or use of immunosuppressive drugs.","65 Years",{"count":330,"type":20},60,[332],"PHASE4","This study aims to evaluate whether probiotics can help maintain a healthy gut microbiome in patients receiving prophylactic antibiotics during elective orthopedic surgery. Antibiotics, while effective in preventing infections, can disrupt the balance of gut bacteria, leading to dysbiosis. The study hypothesizes that the use of probiotics during the perioperative period can prevent or reduce this disruption, supporting gut health and overall well-being. The research seeks to answer whether combining probiotics with routine antibiotic prophylaxis can preserve gut microbiome balance and improve patient outcomes.",[335,308,336,244,337],"Dysbiosis","Microbiome Analysis","Antibiotic Prophylaxis",[339,340,341,342,337,343,344,345],"Gut Microbiome","Intestinal Dysbiosis","Surgical Site Infection","Probiotics","Human Milk Oligosaccharides (HMO)","Shotgun Metagenomic Sequencing","Short-Chain Fatty Acids (SCFAs)","2025-01-18",{"date":348,"type":38},"2025-01-24",{"date":316,"type":20},{"date":351,"type":20},"2025-10-01",{"name":353,"class":45},"Acibadem Maslak Hospital",6]